NEW YORK (GenomeWeb) – Cofactor Genomics today said that it has been named a certified service provider for Agilent's SureSelect Methyl-Seq target enrichment.
The St. Louis-based firm said that it has "built one of the most comprehensive methylation analysis services in the industry and is able to handle every piece of the project, from DNA extraction to analysis."
"One of the next logical steps in understanding genetic modulation by modification is to assess the methylation state of DNA," Cofactor Genomics CSO Jon Armstrong said in a statement. "We … look forward to providing ground-breaking results in the study of epigenetics with their products."
Last September Cofactor received a $300,000 grant from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute to identify sites of epigenetic modifications that contribute to cardiovascular disease endpoints.